Ionis Pharmaceuticals (IONS) Accumulated Depreciation & Amortization (2016 - 2025)
Ionis Pharmaceuticals (IONS) has 11 years of Accumulated Depreciation & Amortization data on record, last reported at -$53.0 million in Q4 2024.
- For Q4 2024, Accumulated Depreciation & Amortization rose 13.36% year-over-year to -$53.0 million; the TTM value through Dec 2024 reached -$53.0 million, up 13.36%, while the annual FY2024 figure was -$53.0 million, 13.36% up from the prior year.
- Accumulated Depreciation & Amortization reached -$53.0 million in Q4 2024 per IONS's latest filing, up from -$61.2 million in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $57000.0 in Q4 2022 and bottomed at -$163.8 million in Q4 2020.
- Average Accumulated Depreciation & Amortization over 5 years is -$62.4 million, with a median of -$53.0 million recorded in 2024.
- Peak YoY movement for Accumulated Depreciation & Amortization: surged 100.17% in 2022, then tumbled 107466.67% in 2023.
- A 5-year view of Accumulated Depreciation & Amortization shows it stood at -$163.8 million in 2020, then skyrocketed by 79.23% to -$34.0 million in 2021, then skyrocketed by 100.17% to $57000.0 in 2022, then crashed by 107466.67% to -$61.2 million in 2023, then grew by 13.36% to -$53.0 million in 2024.
- Per Business Quant database, its latest 3 readings for Accumulated Depreciation & Amortization were -$53.0 million in Q4 2024, -$61.2 million in Q4 2023, and $57000.0 in Q4 2022.